Characterization of P‐glycoprotein orthologs from human, sheep, pig, dog, and cat
Journal of Veterinary Pharmacology and Therapeutics · 2023
DOI: 10.1111/jvp.13386 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Veterinary Pharmacology and Therapeutics, 2023. Verfasst von Mina Azimi und 6 weiteren Autor:innen. Beteiligte Einrichtung: Apricity Therapeutics, Inc., San Francisco, California, USA. Hauptthemen laut MEDLINE: ATP Binding Cassette Transporter, Subfamily B, Member 1, Digoxin. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 70 Literaturangaben. Gefördert von: NIH HHS, National Institutes of Health, Small Business Innovation Research.
Abstract (Originalsprache)
The ATP‐binding cassette transporter P‐glycoprotein (P‐gp) limits the oral bioavailability of many drugs. Although P‐gp has been well studied in humans and mice, little is known about the substrate specificities of many of its species orthologs. To address this, we performed in vitro analysis of P‐gp transporter function using HEK293 cells stably expressing human, ovine, porcine, canine, and feline P‐gp. We also employed a human physiologically based pharmacokinetic (PBPK) model to assess variations in digoxin exposure resulting from altered P‐gp function. Compared to human P‐gp, sheep P‐gp had significantly less digoxin efflux (2.3‐fold ±0.04 vs. 1.8‐fold ±0.03, p < .0001) and all species orthologs had significantly less quinidine efflux compared with human P‐gp ( p < .05). Human P‐gp also had significantly greater efflux of talinolol compared to sheep and dog P‐gp (1.9‐fold ±0.04 vs. 1.6‐fold ±0.06, p = .003 and 1.6‐fold ±0.05, p = .0002, respectively). P‐gp expression protected all lines against paclitaxel‐induced toxicity, with sheep P‐gp being significantly less protective. The inhibitor verapamil demonstrated dose‐dependent inhibition of all P‐gp orthologs. Finally, a PBPK model showed digoxin exposure was sensitive to altered P‐gp activity. Overall, our study found that species differences in this major drug transporter exist and that the appropriate species ortholog of P‐gp should be evaluated during veterinary drug development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Apricity Therapeutics, Inc., San Francisco, California, USA.
- Department of Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, California, USA.
- Evviva Sciences, Fremont, California, USA.
- Department of Anesthesia and Perioperative Care, University of California San Francisco, San Francisco, California, USA.
ORCID-Profile: Mina Azimi, Andrew Riselli
Förderung
- NIH HHS
- National Institutes of Health
- Small Business Innovation Research
Zitieren
APA
Azimi, M., Yee, S. W., Riselli, A., Silva, D. B., Giacomini, C. P., Giacomini, K. M., & Brett, C. M. (2023). Characterization of P‐glycoprotein orthologs from human, sheep, pig, dog, and cat. Journal of Veterinary Pharmacology and Therapeutics. https://doi.org/10.1111/jvp.13386
Vancouver
Azimi M, Yee SW, Riselli A, Silva DB, Giacomini CP, Giacomini KM, et al. Characterization of P‐glycoprotein orthologs from human, sheep, pig, dog, and cat. Journal of Veterinary Pharmacology and Therapeutics. 2023. doi:10.1111/jvp.13386
BibTeX
@article{Azimi2023,
author = {Azimi, Mina and Yee, Sook Wah and Riselli, Andrew and Silva, Dina Buitrago and Giacomini, Craig P and Giacomini, Kathleen M and Brett, Claire M},
title = {Characterization of P‐glycoprotein orthologs from human, sheep, pig, dog, and cat},
journal = {Journal of Veterinary Pharmacology and Therapeutics},
year = {2023},
doi = {10.1111/jvp.13386}
}
EUVIMED